APA

Docta R. Y., Ferronha T., Sanderson J. P., Weissensteiner T., Pope G. R., Bennett A. D., Pumphrey N. J., Ferjentsik Z., Quinn L. L., Wiedermann G. E., Anderson V. E., Saini M., Maroto M., Norry E. & Gerry A. B. (20200615). Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. : Hepatology (Baltimore, Md.).

Chicago

Docta Roslin Y, Ferronha Tiago, Sanderson Joseph P, Weissensteiner Thomas, Pope George R, Bennett Alan D, Pumphrey Nicholas J, Ferjentsik Zoltan, Quinn Laura L, Wiedermann Guy E, Anderson Victoria E, Saini Manoj, Maroto Miguel, Norry Elliot and Gerry Andrew B. 20200615. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. : Hepatology (Baltimore, Md.).

Harvard

Docta R. Y., Ferronha T., Sanderson J. P., Weissensteiner T., Pope G. R., Bennett A. D., Pumphrey N. J., Ferjentsik Z., Quinn L. L., Wiedermann G. E., Anderson V. E., Saini M., Maroto M., Norry E. and Gerry A. B. (20200615). Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. : Hepatology (Baltimore, Md.).

MLA

Docta Roslin Y, Ferronha Tiago, Sanderson Joseph P, Weissensteiner Thomas, Pope George R, Bennett Alan D, Pumphrey Nicholas J, Ferjentsik Zoltan, Quinn Laura L, Wiedermann Guy E, Anderson Victoria E, Saini Manoj, Maroto Miguel, Norry Elliot and Gerry Andrew B. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer. : Hepatology (Baltimore, Md.). 20200615.